All In Biotech

Drug Trial Radar · NCT00524862

Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death

Selective Strategy to Manage Arrhythmia Risk and Therapy With ICD

Last checked: Nov 20, 2026Latest source record: Jul 31, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 5,000 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

5,000

Planned (sponsor's estimate)

Start

Oct 2007

Primary completion

Apr 2011

Study completion Apr 2011

Sponsor

Lead sponsor
Unity Health TorontoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long Term Care
First posted
Sep 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Recent ACC/AHA/ESC guidelines recommend prophylactic ICD implantation in most patients with coronary heart disease and LVEF \< 40%. Current Canadian guidelines recommend ICDs for primary prophylaxis in CAD patients with LVEF \< 30% (Class I recommendation). There are very sparse data to recommend ICD implantation in patients with EF between 30 and 40 %. This study will randomize patients with CHD and an EF between 30 and 40% to ICD therapy vs. No ICD therapy. The primary outcome is mortality and the study is powered as a non-inferiority trial to test the hypothesis that mortality in patients with no ICD is not more than 1% greater (absolute yearly increase) than patients receiving an ICD.

Conditions

  • Coronary Heart Disease
  • Congestive Heart Failure
  • Ventricular Dysfunction
  • Low Cardiac Output
  • Sudden Cardiac Death

Interventions

  • Optimized medical therapyDrug

    Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated

  • Implantable Cardioverter DefibrillatorDevice

    an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortalityTime frame: minimum 1 year follow-up (maximum 6 year)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Hamilton Health Sciences - Hamilton General

    Hamilton, Ontario, Canada

  • Kingston General Hospital

    Kingston, Ontario, Canada

  • London Health Sciences - University Campus

    London, Ontario, Canada

  • Trillium Health Centre - Mississauga

    Mississauga, Ontario, Canada

  • Southlake Regional Health Centre

    Newmarket, Ontario, Canada

  • University of Ottawa Heart Institute

    Ottawa, Ontario, Canada

  • Rouge Valley Health System - Centenary

    Scarborough Village, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • University Health Network - Toronto General Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.